← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Appajosyula Sireesh
Chief Executive Officer | Director | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001901565
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 2
- Purchases · 24M
- 4
- Average purchase
- $62.8K
- Median purchase
- $70.5K
- Gross purchase value
- $251.1K
Companies: Hepion Pharmaceuticals, Inc. | Tharimmune, Inc.
4 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-12 | Hepion Pharmaceuticals, Inc. | HEPA | Officer | $100.0K | Open filing |
| 2026-04-27 | Hepion Pharmaceuticals, Inc. | HEPA | Director | $50.0K | Open filing |
| 2025-06-23 | Tharimmune, Inc. | THAR | Chief Executive Officer | Officer | $91.0K | Open filing |
| 2024-11-13 | Tharimmune, Inc. | THAR | Officer | $10.1K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 50.0% (2/4) | 50.0% (1/2) | +17.1% | +17.1% | -13.3% |
| 20D | 2Small Sample | 50.0% (2/4) | 100.0% (2/2) | +32.5% | +32.5% | +16.0% |
| 60D | 1Small Sample | 33.3% (1/3) | 0.0% (0/1) | -29.3% | -29.3% | -29.3% |
| 120D | 0No Data | 0.0% (0/3) | — | — | — | — |
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ $100k
- 1/4
- Cluster buying · 15D
- 3/4
- Buying the dip
- 2/2
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.